Trimethoprim-sulfamethoxazole-induced intrahepatic cholestasis

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Trimethoprim - sulfamethoxazole (Septra®) is used extensively in children for treatment of uninary tract infections. Recently, long-term prophylaxis with trimethoprim-sulfamethoxazole against urinary tract infection has been shown to be efficacious. Although sulfamethoxazole has occasionally been associated with hepatitis in which hepatocellular necrosis was the prominent feature trimethoprim has not been reported to cause hepatic injury. Intrahepatic cholestatis with hepatocellular necrosis from trimethoprim-sulfamethoxazole has been reported in a 16-year-old boy, but intrahepatic cholestatis without hepatocellular damage has been reported in children. This is a case report of a 5-year-old child in whom intrahepatic cholestatis developed after treatment with trimethoprim-sulfamethoxazole given for prophylaxis of urinary tract infection.

Original languageEnglish (US)
Pages (from-to)212-214
Number of pages3
JournalClinical Pediatrics
Volume22
Issue number3
Publication statusPublished - 1983
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this